Wall Street analysts expect Teligent, Inc. (NASDAQ:TLGT) to report earnings of ($0.11) per share for the current quarter, according to Zacks Investment Research. Three analysts have made estimates for Teligent’s earnings, with the highest EPS estimate coming in at ($0.09) and the lowest estimate coming in at ($0.13). Teligent reported earnings of $0.01 per share in the same quarter last year, which indicates a negative year over year growth rate of 1,200%. The business is expected to report its next quarterly earnings results on Tuesday, March 6th.
On average, analysts expect that Teligent will report full year earnings of ($0.14) per share for the current fiscal year, with EPS estimates ranging from ($0.15) to ($0.11). For the next fiscal year, analysts forecast that the company will report earnings of $0.06 per share, with EPS estimates ranging from ($0.06) to $0.15. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that follow Teligent.
Teligent (NASDAQ:TLGT) last released its earnings results on Monday, November 6th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.07). Teligent had a negative net margin of 16.95% and a negative return on equity of 6.51%. The company had revenue of $13.65 million during the quarter, compared to analyst estimates of $19.12 million. During the same period in the previous year, the company posted $0.01 EPS. The company’s quarterly revenue was down 15.5% compared to the same quarter last year.
Teligent (NASDAQ:TLGT) traded up $0.06 during mid-day trading on Thursday, reaching $3.91. The company had a trading volume of 417,000 shares, compared to its average volume of 391,650. Teligent has a fifty-two week low of $2.82 and a fifty-two week high of $9.54. The company has a current ratio of 3.28, a quick ratio of 2.71 and a debt-to-equity ratio of 2.23. The firm has a market cap of $217.87, a P/E ratio of -17.77, a P/E/G ratio of 77.00 and a beta of 1.34.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Janus Henderson Group PLC bought a new stake in Teligent during the 2nd quarter worth approximately $51,431,000. Pembroke Management LTD increased its holdings in Teligent by 2.9% during the 3rd quarter. Pembroke Management LTD now owns 2,326,621 shares of the company’s stock worth $15,612,000 after purchasing an additional 65,200 shares in the last quarter. Vanguard Group Inc. increased its holdings in Teligent by 3.6% during the 2nd quarter. Vanguard Group Inc. now owns 2,048,984 shares of the company’s stock worth $18,748,000 after purchasing an additional 72,093 shares in the last quarter. Elk Creek Partners LLC increased its holdings in Teligent by 0.9% during the 3rd quarter. Elk Creek Partners LLC now owns 1,709,841 shares of the company’s stock worth $11,473,000 after purchasing an additional 15,087 shares in the last quarter. Finally, Stifel Financial Corp increased its holdings in Teligent by 51.7% during the 3rd quarter. Stifel Financial Corp now owns 1,141,741 shares of the company’s stock worth $7,685,000 after purchasing an additional 389,307 shares in the last quarter. 70.83% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This piece of content was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/04/analysts-expect-teligent-inc-tlgt-to-post-0-11-earnings-per-share.html.
Teligent, Inc is a specialty generic pharmaceutical company. Under the Company’s own label, it markets and sells generic injectable pharmaceutical products in the United States and Canada. In the United States it marketed 16 generic topical pharmaceutical products and four branded generic pharmaceutical products, as of December 31, 2016.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Teligent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teligent and related companies with MarketBeat.com's FREE daily email newsletter.